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Abstract
Multidrug resistance mediated by P-glycoprotein in cancer cells has been a major issue that cripples the efficacy of
chemotherapy agents. Aimed for improved efficacy against resistant cancer cells, we designed and synthesized 25
oxindole derivatives based on indirubin by structure-activity relationship analysis. The most potent one was named PH II-
7, which was effective against 18 cancer cell lines and 5 resistant cell lines in MTT assay. It also significantly inhibited the
resistant xenograft tumor growth in mouse model. In cell cycle assay and apoptosis assay conducted with flow cytometry,
PH II-7 induced S phase cell cycle arrest and apoptosis even in resistant cells. Consistently revealed by real-time PCR, it
modulates the expression of genes related to the cell cycle and apoptosis in these cells, which may contributes to its
efficacy against them. By side-chain modification and FITC-labeling of PH II-7, we were able to show with confocal
microscopy that not only it was not pumped by P-glycoprotein, it also attenuated the efflux of Adriamycin by P-
glycoprotein in MDR tumor cells. Real-time PCR and western blot analysis showed that PH II-7 down-regulated MDR1 gene
via protein kinase C alpha (PKCA) pathway, with c-FOS and c-JUN as possible mediators. Taken together, PH II-7 is a dual-
functional compound that features both the cytotoxicity against cancer cells and the inhibitory effect on P-gp mediated
drug efflux.
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Introduction
Clinical cancer treatments still rely heavily on chemotherapy,
especially for metastatic cancers and hematological malignancies.
The major problem that hinders the cytotoxic effect of
chemotherapy is the energy-dependent active efflux of multiple
drugs in certain cancer cells, a phenomenon initially reported in
1973 [1] as multi-drug resistance (MDR). P-glycoprotein(P-gp),
which is a member of the ATP-binding cassettes(ABC), was
subsequently revealed as a culprit [2]. Other ABC family
members, e.g. ABCC1 [3–5], ABCG2 [6–8], have since been
shown to affect drug efflux. Up to 28 of the total 48 human ABC
genes are possibly related to MDR [9].
The P-gp represents the most well established mechanism for
MDR, with many clinical chemotherapy drugs being its
substrates. The importance of P-gp proposed a strong rationale
for the inhibition strategy, hence three generations of P-gp
inhibitors have been developed, but most of which were
discontinued for pharmacological or pharmacokinetic side effects
[10–15]. Other P-gp-targeting anti-MDR strategies include but
not limited to: P-gp specific peptides [16] or antibodies [17],
downregulation of MDR1 gene with transcriptional repressors
[18,19] or siRNAs [20,21], novel agents that are not substrates of
P-gp [22,23], or encapsulation of chemo-agents to evade P-gp
efflux [24].
The traditional Chinese medicine has a large pharmacopoeia
that includes over 5500 natural sources, 82.8% of which are
plants. These substances form the basis of 100,000 to 500,000
prescriptions and may be a good source for the discovery of new
antitumor compounds [25]. Our lab identified indirubin as the
active agent of Danggui Longhui Wan (an 11-component, effective
recipe against chronic myeloid leukemia) [26–31]. Hoessel et al.
reported indirubin as a potent cyclin-dependent kinase inhibitor
and synthesized indirubin-3-monoxime [32], which arrests the cell
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range of cells. Based on the template of indirubin, we designed and
synthesized a series of oxindole derivatives; MTT assay and SAR
(structure-activity relationship) study were used to screen for the
most effective compound, through which we identified PH II-7,
which effectively kills sensitive and multi-drug resistant tumor cells
in vitro and in vivo.
Results
SAR analysis based development of PH II-7
Indirubin is composed of two structural units connected by a 2-
39 d-bond, one is an indigoid and the other one is an indigoid
isomer (Fig. 1). Indigo, with no bioactivity for tumor inhibition, is
composed of two identical indigoid structural units connected by a
2-29 d-bond, indicating the bioactivity does not come with the
indigoid, but with the indigoid isomer. We kept the indigoid
isomer intact and modified the indigoid to generate three
derivatives: I, II, and III. Through SAR and MTT analysis, we
screened out compound II. Based on it we then synthesized 25
derivatives (Table S1) , among which PH II-7 was recognized as
the most potent by further SAR analysis and MTT assay (Table
S1,Fig. 1).
PH II-7 shows potent cytotoxicity against both sensitive
and MDR tumor cell lines
Wth MTT assay, We tested PH II-7 against 18 human
cancer cells lines (Fig. 2A), including 5 pairs of MDR sublines
and their parental cell lines (Fig. 2B). PH II-7 showed universal
potency for all of the tested cell lines; the effect was especially
notable for MDR cells which defy most conventional chemo-
therapeutic agents. The IC50 values of Adriamycin in the CML
cell line K562/A02, the AML cell line HL60/ADR, and the
breast cancer cell line MCF7/ADR, are 93.93, 377.13 and
17.88 times as resistant, respectively, compared with their
parental cell lines. However, with PH II-7, the differences only
ranged from 0.7 to 5.3 folds. When combined with PH II-7
(0.5 mM), the efficacy of ADM against MDR cancer cell lines
(K562/A02, MCF7/ADR) was greatly augmented, the same
combinatorial effect was also observed with another chemo-
therapy agent Vincristine (VCR) which, like ADM, is also a
substrate of P-gp (Fig. 2C).
Figure 1. Schematic illustration of the process that leads to the discovery of PH II-7. From Danggui Longhui Wan to Indigo naturalis, then
to indirubin, the anti-cancer bioactivity was finally attributed to oxindole, the effector moiety of indirubin, which was kept intact in the further
modifications that lead to 3 kinds of compounds. Based on compound II, 25 candidates were generated by different modifications, among them PH
II-7 was finally screened out by structure-activity relationship analysis and MTT assay.
doi:10.1371/journal.pone.0032782.g001
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Relative Tumor Volumes (RTV) of K562 and K562/A02
xenograft tumors treated with ADM or PH II-7 were calculated
(Fig. 3A). ADM (5 mg/ml) exhibited an inhibitory rate of 70% on
K562 cell xenograft tumors, but only 8.8% on K562/A02 cell
xenograft tumors. The latter substantially resisted ADM treat-
ment. Meantime, 25 mg/ml of PH II-7 inhibited K562 and
K562/A02 xenograft tumors by 65.27% (P,0.05) and 51.94%
(P,0.05), respectively, and no substantial resistance was observed.
In all of the treated groups, PH II-7 was well tolerated; without
considerable change in Relative Body Weight (RBW) even at the
highest dose (5% increase, P.0.05) (Fig. 3B). While ADM was
generally ineffective, PH II-7 substantially inhibited MDR
xenograft tumor growth.
PH II-7 induces apoptosis in both sensitive and resistant
cell lines
A series of concentrations (300 nM, 600 nM, and 750 nM) of
PH II-7 induced apoptosis in K562 and K562/A02 cells (Fig. 4A).
The percentage of cells in the early phase of apoptosis increased
with the concentration of PH II-7 and there was no considerable
difference in the PH II-7 dose/effect ratio between the two cell
lines. ADM (100 nM) showed about the same apoptosis-inducing
effect as 0.6 mM PH II-7 did in K562 cells, but failed to do so in
K562/A02 cells(Fig. 4A). When ADM is used in combination with
PH II-7, the pro-apoptotic effect was enhanced in a PH II-7 dose-
dependent manner (Fig. 4B).
PH II-7 induces cell cycle arrest in both sensitive and
resistant cell lines
we quantitatively evaluated the cell cycle arrest induced by PH
II-7. The result (Fig. 5A) shows that PH II-7 caused a substantial
increase in the percentage of S phase cells (from 44.10% to
70.61% and from 56.18% to 75.40%, in K562 and K562/A02
cells respectively), this contrasts with the inability of ADM to
induce cycle arrest in K562/A02 at the dose effective to K562 cells
(Fig. 5B). Furthermore, the percentage of cells inhibited in S phase
increased with the concentration of PH II-7.
CLSM imaging of labeled PH II-7 and ADM intracellular
distribution
We made side chain decoration on PH II-7 (3-nitrobenzylidene-
1-(3-aminopropyl) indoline-2-one, or PH II-7-NH2, method
described in supplement), to conjugate it with Fluorescein
Figure 3. Efficacy of PH II-7 in K562 and K562/A02 xenograft tumors. (A) K562 and K562/A02 xenograft tumors were treated with
PBS(control), 25 mg/kg PH II-7, 50 mg/kg PH II-7, 4 mg/kg ADM, separately. The relative tumor volumes (RTV) were measured and calculated over 11
days (n=5). (B) Relative Body Weight (RBW) of each group (n=5) (* : P,0.05).
doi:10.1371/journal.pone.0032782.g003
Figure 2. Efficacy of PH II-7 in cancer cell lines. (A) IC50 value of PH II-7 in various human cancer cell lines. IC50 values (mean 6 SD, mM)
were calculated from 3 independent experiments. (B) Cytotoxicity comparison between PH II-7 and ADM in five pairs of human tumor cell lines and
their MDR sublines. IC50 values (mean 6 SD, mM) were calculated from 3 independent experiments. The 5 MDR sublines are A549
DDP, KB/v200, MCF-
7/ADR, HL60/ADR, and K562/A02 respectively. (C) The IC50 values(mean 6 SD, mM, calculated from 3 independent experiments) of Adriamycin (ADM,
upper panel) and Vincristine (VCR, lower panel) in K562, K562/A02, MCF7, MCF7/ADR cells, with or without PH II-7 (0.5 mM).
doi:10.1371/journal.pone.0032782.g002
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FITC-labeled PH II-7 aggregated in the nuclei of both the K562
and the K562/A02 cells in a time-dependent manner. However,
there was no considerable change in the overall intracellular
concentration of PH II-7 between the two cell lines at the three
time points (Fig. 6B). In comparison, the intracellular concentra-
tion of ADM more sharply decreased in the K562/A02 cells than
in the K562 cells (Fig. 6C). The decrease could be reversed (in a
time-dependent manner) by the administration of PH II-7 at a
very low concentration (300 nM) (Fig. 6C).
Measurement of ADM intracellular accumulation and
efflux by Flow Cytometry
We quantitatively defined the effect of PH II-7 on drug
accumulation and efflux by flow cytometry. The intracellular drug
concentration increase was in a PH II-7 dose-dependent manner
(Fig. 6D), indicated that PH II-7 partially inhibited the drug efflux
in K562/A02 cells.
PH II-7’s effect on genome wide mRNA profile
We investigated changes of the genome wide mRNA profiles in
cells treated with PH II-7. The cRNA was generated from isolated
total RNA samples from K562 and K562/A02 cells treated for
48 hours with 200 nM of PH II-7; cRNA was labeled, hybridized
and scanned according to standard Affymetrix protocols. Affyme-
trix Human U133 Plus 2.0 Arrays, which contain more than
54,000 probe sets, were used for each RNA sample. We
determined alterations in transcription levels by comparing our
information with data derived from the same cell lines treated with
PBS (as a control) under identical conditions. PH II-7-responsive
genes were defined as those whose expression levels were up-
regulated or down-regulated by PH II-7 by more than two folds.
These genes were assigned to six groups: those up-regulated by PH
II-7 in both sublines, in K562/A02 only, or in K562 only and
those down-regulated by PH II-7 in both sublines, in K562/A02
only, or in K562 only.
We found a series of PH II-7 responsive genes including cell
cycle related genes (such as CHK1, P21, and HBP1), apoptosis
related genes (such as PML), MDR related genes (such as MDR1,
PKCA) (Fig. 7A), these are put to further screening and validation
with real-time PCR. Gene ontology analysis revealed over-
represented functional classes of genes that are either up-regulated
or down-regulated by PH II-7 (Table 1).
Relative quantification of interested genes by real-time
PCR
Expression variations of some important genes are further
validated and qualified by real-time relative quantitative PCR
Figure 4. PH II-7 induces apoptosis in K562 and K562/A02 cells. (A) Induction of apoptosis by PH II-7 and ADM (both treated for 24 hours,
concentrations indicated in the figure) in K562 or K562/A02 cells. (B) The induction of apoptosis in K562 and K562/A02 cells by different
concentrations of PH II-7(300 nM, 600 nM, 700 nM), either alone or in combination with ADM(100 nM).
doi:10.1371/journal.pone.0032782.g004
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PBS or PH II-7 (200 nM) for 48 hours, and the total RNA was
extracted, reverse-transcribed to cDNA, which was used for the
real-time relative quantitative PCR. Several cell cycle related
genes CHK1, P21, and HBP, and the apoptosis related gene PML,
are significantly up-regulated by PH II-7 treatment, and two
MDR related genes PKCA and MDR1, were significantly down-
regulated (P,0.05, n=4) (Fig. 7B).
PH II-7 reduces MDR1/P-gp expression through PKCA
related pathway
We used the PKCA activator, 12-O-Tetradecanoylphorbol-13-
acetate(TPA), and the PKCA inhibitor, Calphostin. The naı ¨ve
expression of MDR1/P-gp is critically higher in K562/A02 than
in K562. TPA induces MDR1/P-gp expression in K562, which is
significantly antagonized by PH II-7(P,0.05). As does Calphostin,
PH II-7 reduces MDR1/P-gp expression in K562/A02, the effect
is significantly antagonized by TPA (P,0.05). (Fig. 8A,B). The
PKCA mRNA and protein levels, which are critically higher in
K562/A02 than in K562, are significantly reduced by either PH
II-7 (P,0.05) or PKCA siRNA (P,0.05) (Fig. 8C,D). Interesting-
ly, two transcription factors, c-JUN and c-FOS, were also
downregulated by PKCA siRNA, along with PKCA and MDR1
(Fig. 8E).
Discussion
Both inhibition of P-gp efflux function and downregulation of
MDR1/P-gp expression are theoretically effective strategies to
reverse MDR, and many dedicated P-gp inhibitors or dedicated
MDR1 expression regulators have been developed, but their
efficacies are still to be improved. Even with satisfying efficacy,
they can only be supplements to classic chemotherapy agents,
hence in extra, could cause undesirable drug-drug interactions,
toxicities or pharmacokinetic side effects [10,11,13,15].
Being a potent cancer cell-killing agent in the first place, PH II-7
is also effective in inhibiting P-gp efflux function and in reducing
MDR1/P-gp expression, thus represents a promising lead
compound in MDR cancer therapy.
Primarily, PH II-7 is a potent anti-tumor agent, especially
against MDR tumor. PH II-7 has a broad antitumor spectrum
(affecting at least 16 human cancer cell lines); it effectively
inhibited the growth of all tested cancer cells at comparatively low
concentrations (Fig. 2A). Compared to the chemotherapeutic
Figure 5. PH II-7 induces S phase cell cycle arrest in K562 and K562/A02 cells. (A) PH II-7 induces cell cycle S phase arrest in a concentration-
dependent manner in K562 and K562/A02 cells, the cells were treated with the indicated concentrations of PH II-7 for 24 hours. (B) ADM induces cell
cycle S-phase arrest in a concentration-dependent manner in K562 and K562/A02 cells; the cells were treated with the indicated concentration of
ADM for 24 hours. The number of events is plotted against fluorescence intensity (DNA content).
doi:10.1371/journal.pone.0032782.g005
Figure 6. The intracellular distribution of PH II-7 in K562 and K562/A02 cells and its regulation of intracellular ADM concentration
in K562/A02 cells. (A) Synthesis of 3-nitrobenzylidene-1-(3-aminopropyl) indoline-2-one (PH II-7-NH2), and the conjugation of it with FITC. (B)The
intracellular locations of PH II-7 in K562 and K562/A02 cells at 0.5 hour, 3 hours, and 5.5 hours. Green dots indicate the FITC-labeled PH II-7 derivative.
Blue dots indicate cell nuclei. (C) Adriamycin intracellular concentration augmented in a time dependent manner in PH II-7 treated K562/A02 cells. (D)
Modulation of ADM intracellular concentration by PH II-7 in K562/A02 cells measured by flow cytometry. The X-axis represents intracellular ADM
concentration, while the Y-axis represents the cell count.
doi:10.1371/journal.pone.0032782.g006
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cancer cell lines and their corresponding MDR sublines that are
highly resistant to ADM (Fig. 2B). The potency against MDR
tumor cells indicates that PH II-7 could have different action
modes compared with conventional chemotherapeutic agents.
Furthermore, in combinatorial treatment, PH II-7(0.5 mM, much
lower than IC50), significantly potentiates ADM and Vincristine
(VCR) (Both are substrates of P-gp) against MDR cancer cells
(Fig. 2C), Which suggests certain degree of re-sensitization of P-gp
overexpressing MDR cells by PH II-7. Consistently, when ADM is
only effective against the xenograft tumor of K562 but not that of
K562/A02, PH II-7 is effective on both (Fig. 3A) at doses better
tolerated than ADM, without significant host body weight loss
(Fig. 3B).
The potency of PH II-7 against MDR cancer cells can at least
be partially attributed to its ability to induce apoptosis and cell
cycle arrest in MDR cells.
MDR cancer cells treated with chemotherapeutic agents
develop apoptosis resistance or a reduced apoptosis response.
Pallis reported that P-gp has a drug-independent role in the
inhibition of in vitro apoptosis in AML blasts [33]. The
modulation of cytokine efflux, signaling lipids and intracellular
pH have all been suggested as ways by which P-gp may affect
cellular resistance to apoptosis [34]. The Adriamycin selection of
the human multiple myeloma cell line RPMI 8226 led to changes
in gene expression that reduced the apoptotic response to death-
inducing stimuli; this reduction contributes to the multidrug
resistance phenotype [35]. ADM (100 nM) induced significant
apoptosis in K562 cells but failed to do so in K562/A02 cells
(Fig. 4A). Notably, apoptosis was induced in K562 and K562/A02
cells treated with PH II-7 despite the concentration variation
(Fig. 4A), and the apoptosis resistance to ADM treatment can be
reversed by PH II-7 dose dependently (Fig. 4B), which indicates
that PH II-7 is capable of overcoming apoptosis resistance and
inducing significant apoptosis in K562/A02 cells.
Resistance to cell cycle arrest is another way P-gp helps MDR
cancer cells survive the conventional chemo-agents [36]. Previous
studies have demonstrated that certain indirubin derivatives are
Figure 7. Regulation of gene expression by PH II-7 in K562 and K562/A02 cells. The K562 and K562/A02 cells were treated with PBS or PH
II-7 (200 nM) for 48 hours, (A)Venn diagrams showing numbers of PH II-7-responsive genes in K562 and K562/A02 cells. PH II-7-responsive genes were
defined as genes whose expression levels were up-regulated or down-regulated by PH II-7 (200 nM, 48 hours) by more than 2-fold and were assigned
to 6 groups: up-regulated by PH II-7 in both cell lines, K562/A02 only, and K562 only; down-regulated by PH II-7 in both cell lines, K562/A02 only, and
K562 only. (B) Genes showed significant expression level change compared with control (P,0.05) in further validation by RT-qPCR. Data represent
results from at least 4 separate experiments.
doi:10.1371/journal.pone.0032782.g007
Table 1. Gene Ontology analysis, over-represented functional classes of genes.
Up-regulated by PH II-7 Down-regulated by PH II-7
Cellular process (P,0.003) Cell cycle (P,0.02)
Apoptosis (P,0.03) Cellular physiological process (P,0.03)
Programmed cell death (P,0.03) Cytoskeleton (P,0.006)
Phosphatidylinositol signaling system (P,0.05)
doi:10.1371/journal.pone.0032782.t001
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data indicate that PH II-7 substantially inhibited the cell cycles of
not only K562 but also K562/A02 cells in S phase (Fig. 5A,B).
Physiologically, by ensuring that the onset of mitosis is dependent
on the completion of DNA replication, the S phase checkpoint
prevents the generation of aneuploid daughter cells that are not
viable. MDR cells inhibited in S phase by PH II-7 are not able to
enter G2 and M phases and are therefore prevented from
undergoing mitosis and further proliferation.
Being a very potent anti-cancer agent itself, PH II-7 features yet
another much-needed characteristic against MDR cancer cells:
inhibition of P-gp mediated drug effux. K562/A02 cells
overexpress P-gp; silencing of MDR1 by RNAi resulted in an
attenuated MDR phenotype and increased drug efficacy [4–8].
CLSM imaging revealed a dramatic decrease of ADM retention in
K562/A02 cells compared with K562 cells. However, the
intracellular retention of FITC-labeled PH II-7 did not signifi-
cantly vary between K562 and K562/A02 cells; the PH II-7
molecules redistributed into the nucleus over time, rather than
being pumped out of the cells like ADM(Fig. 6B). Hence PH II-7 is
not influenced by the drug efflux mediated MDR mechanism,
quite possibly because it is not a substrate of P-gp.
The function of P-gp can be influenced by small molecule
compounds [40–43]. K562/A02 cells that were pretreated with a
very low concentration (,IC10) of PH II-7 showed attenuated
drug efflux that was dependent on both time and concentration
(Fig. 6C,D). This effect may at least partially contribute to the
blunted P-gp funtion in cells treated with PH II-7. We found that
PH II-7 reduced the expression level of MDR1, along with protein
kinase C alpha (PKCA), a gene that is intimately related to MDR1
expression(Fig. 7B, Fig. 8A–D). Others reported that PKCA acts
as a regulator of MDR1 expression, which is supported by the
Figure 8. PH II-7 regulates MDR1/P-gp expression through a PKCA pathway. (A) The expression of MDR1 in K562 and K562/A02 cells with or
without the treatments of either PH II-7 (200 nM), TPA (100 nM), Calphostin (1 mM), or their different combinations, detected by RT-qPCR. Expression
levels are normalized to that of untreated K562/A02 (as 1) (n=4). (B) The surface expression of MDR1 in K562 and K562/A02 cells with or without
treatments of either PH II-7, TPA, Calphostin, or their different combinations, detected by flow cytometry(n=4). (C) mRNA expression of PKCA in K562,
K562/A02, K562/A02 treated with PH II-7(200 nM), K562/A02 treated with siRNA targeting PKCA, detected by RT-qPCR (n=4). (D) Western-blot,
protein level of PKCA in K562/A02, K562/A02 treated with control siRNA(scramble), K562/A02 treated with siRNA targeting PKCA, K562/A02 treated
with PH II-7(200 nM), K562. GAPDH was used as an internal control. (E) Transfection of K562/A02 cells with PKCA-targeted siRNA, resulted in mRNA
expression knock down in PKCA, MDR1, and also two transcriptors downstream of PKCA, c-JUN, c-FOS.
doi:10.1371/journal.pone.0032782.g008
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PKCA agonist TPA [44,45] and by the fact that the transfection of
PKC-a antisense cDNA into MCF-7/ADR cells attenuates their
MDR phenotype [46,47]. The induction of MDR1 activity by
PKCA in the presence of TPA can be attenuated by the PKC
inhibitor GF 109203X [48]. Our data indicate that the reduction
of MDR1/P-gp expression by PH II-7 is antagonized by PKCA
activator TPA, while the induction of MDR1/P-gp expression by
TPA is abrogated by PH II-7, which strongly recommends the
involvement of PKCA in PH II-7’s regulation of MDR1(Fig. 8A–
C). Whereas in TPA-alone treated K562/A02 cells, since the
PKCA is congenitally expressed at a high level, no significant
difference in MDR1/Pgp expression was observed(data not
shown). PH II-7 and Calphostin alike can reduce MDR1/P-gp
expression(Fig. 8A,B), while PH II-7 and PKCA siRNA alike can
reduce PKCA expression(Fig. 8C,D), which suggests that PH II-7
downregulates MDR1 by suppressing PKCA expression. Interest-
ingly, two transcription factors c-FOS and c-JUN, which are
downstream under regulation of PKCA [49–52], bind to AP-1 site
as homodimer or heterodimer [53,54]. An AP-1 element exists in
the MDR1 promoter [55,56], and numerous reports confirmed the
regulation of MDR1 expression by c-FOS/c-JUN binding/
activation of AP-1, but debates arise when it comes to ‘how’, some
reported the regulation to be positive [55–58], while some believed
it to be negative [59,60]. The inconsistency could at least be partly
attributed to the different cells and environments upon which these
experiments were conducted. In K562/A02 cells, our data show
that along with the knock-down of PKCA expression, the c-FOS/c-
JUN and MDR1 expressions decreased simultaneously(Fig. 8E),
strongly indicates a positive regulation of MDR1 by c-FOS/c-JUN.
Therefore, with c-FOS/c-JUN as mediators that bridge the PKCA-
to-MDR1 regulation, we propose the possible pathway as: PH II-7
suppresses PKCA expression, and in turn reduces the c-FOS/c-
JUNexpression and their binding/activation of AP-1 element in the
MDR1 promoter region, thus inhibits MDR1/P-gp expression.
Besides PKCA, several other PH II-7 responsive genes revealed
by RT-qPCR are possibly responsible for its efficacy, including
PML, HBP1, CHK1 and P21. PH II-7 treatment in both K562
and K562/A02 cells induced expression of these genes (Fig. 7B).
PML is essential for multiple apoptotic pathways. Analysis of
mouse cells lacking PML has demonstrated that PML is involved
in various apoptotic pathways. Hematopoietic cells and embry-
onic fibroblasts from PML nul,ll mice are resistant to a series of
p53-dependent and p53-independent pro-apoptotic stimuli [61].
We believe that inhibition of PML expression by PH II-7
inevitably contributes to the circumvention of apoptosis resistance
in K562/A02 cells. HBP1 is controlled by p38 mitogen-activated
protein kinase pathway and regulates cell cycle progression via
NADPH oxidase [62,63]. CHK1 has been reported to be
involved in S phase cell cycle arrest. The depletion of CHK1
resulted in the loss of S phase arrest upon incubation with
topoisomerase I inhibitor SN38, which arrests cells in S phase
[64]. CHK1 is also reported to be a an intra-S phase checkpoint,
ensuring the integrity of the arrested replication fork, and CHK1
inhibitor causes global firing of replication origin [65]. Numerous
reports indicate that p21 expression is under the positive
regulation of PKCA [66,67], the overexpression of p21 arrests
cell cycle in S phase [68]. P21 interacts with E2F-1 to regulate
cell progression to guard against unrestricted cell proliferation
[69]. The cell cycle arrest by PH II-7 (Fig. 5A,B) may partially be
attributed to the regulation of PH II-7 on CHK1 and p21. Thus,
these mechanisms, aside from inhibiting and regulating P-gp,
could also be exploited by PH II-7 to exert its efficacy against
cancer cells, especially the resistant ones.
In conclusion, we used indirubin, the active component of the
traditional Chinese medicine Danggui Longhui Wan, as a
template to synthesize the oxindole derivative PH II-7. PH II-7
shows potent broad spectrum antitumor activity, especially against
MDR tumor cells, both in vitro and in vivo. PH II-7 achieved a
much higher intracellular concentration than other chemothera-
peutic agents and significantly induced apoptosis and S phase cell
cycle arrest in MDR tumor cells. These actions occurred through
the altered expression of specific genes and resulted in the effective
inhibition and termination of MDR tumor growth. In addition, in
vitro and in vivo experiments show excellent tumor bearer tolerance.
We further found that PH II-7 effectively inhibits the expression of
MDR1 and impairs the drug efflux function of P-gp by reducing
the expression level of PKCA. Our data suggest that PH II-7 is a
promising lead compound for anti-MDR tumor drug development
and may offer a new solution to the MDR phenomenon. Our
method of discovering PH II-7 represents an effective paradigm of
lead compound development based on traditional Chinese
medicine.
Materials and Methods
Cell culture
Drug-selected cell lines overexpressing P-gp (K562/A02, MCF-
7/ADR, KB/v200 and A549DDP) and MRP-1 (HL60/ADR)
were cultured with Adriamycin (ADM), Vincristine or Cisplatin ,
as previously described [28–33]. K562/A02 cell line showed a
significant (100-fold) increase in drug resistance. TPA (PKC
activator, sigma) and Calphostin C (PKC inhibitor, sigma) were
used for cell treatment in some experiments.
Cytotoxicity Assay
Leukemia cells (2610
4/well) were seeded 96-well tissue culture
plates (Coaster, Charlotte, NC) and treated with derivatives I, X-
substitutes, PH II-7, Adriamycin or PH II-7 plus Adriamycin for
72 hours at 37uC in a 5% CO2 atmosphere. Twenty microliters of
MTT (5 mg/mL) was added to each well and the plates were
incubated for 4 hours, then 100 ml DMSO was added to each well.
The absorbance value of the cells was read at 570 nm using a
spectrophotometer (Model A-5082, SLT Lab Instrumenta,
Grodig, Austria).
Animals
Five to six weeks old female nude mice (BALB/C, nu/nu, body
weight 16–18 g) were obtained from Vital River Laboratories. All
animal studies were conducted according to protocols approved by
the Animal Ethics Committee of the Institute of Hematology &
Hospital of Blood Diseases, Chinese Academy of Medical Sciences
& Peking Union Medical College, with the approval ID of
AEC2009070202. All mice used in this study were bred and
maintained in a specific pathogen-free environment.
In vivo anti-tumor PH II-7
The mice were exposed to total body irradiation (400 rad) to
suppress their residual immune systems and facilitate the
establishment of xenografts. Twelve hours later, the mice were
injected subcutaneously in the right flank with 2610
7 K562 and
K562/A02 cells suspended in PBS. When the tumor volume
reached 40 to 60 mm
3, the animals were randomly assigned to 4
groups, each separately treated (i.p. TID) with 4 mg/kg ADM
alone, 25 mg/kg PH II-7 alone, 50 mg/kg PH II-7 alone, or PBS
(control). Tumor dimensions were measured using a linear caliper
every 2 days and tumor volume (RTV) was calculated using the
equation RTV (mm
3)=a 6b
2/2, where a is the longest diameter
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was calculated by the equation RBW=Wt/Wo, where Wt is the
body weight on day 11, Wo is the body weight on day 0.
Apoptosis assay
K562 and K562/A02 cells were seeded in 6-well plates and
exposed to different concentrations of PH II-7 (0.3 mM, 0.6 mM,
or 0.75 mM) or ADM (100 nM) for 24 hours. To rule out the
influence of PH II-7 cytotoxicity, the concentration was limited to
no more than 0.75 mM. Samples were labeled using an annexin V-
FITC and PI double-staining apoptosis detection kit purchased
from Becton Dickinson (Mountain View, CA). Cells were assayed
using flow cytometry.
Cell cycle test
Logarithmically growing K562 and K562/A02 cells (5610
5)
were seeded in 6-well tissue culture plates (Coaster, Charlotte, NC)
and incubated with different concentrations of PH II-7 or ADM
for 24 hours. Cell harvesting and staining were completed with a
CycleTEST
TM PLUS DNA Reagent Kit purchased from Becton
Dickinson (Mountain View, CA). The percentage of cells in each
cycle phase was calculated with Modfit software (Verity Software
House, U.S).
Flow cytometric measurement of intracellular ADM
concentration
Cells were cultured in 24-well plates and exposed to different
concentrations of PH II-7 for 24 hours, 48 hours and 72 hours.
They were then incubated with ADM for 1 hour and their
intracellular fluorescence was examined by flow cytometry.
Side chain modulation, FITC labeling and intracellular
localization of PH II-7
The names and synthetic protocols for the four compounds
listed in Fig. 4A are as follows:
I 1-(3-chloropropyl) indoline-2,3-dione; the synthesis fol-
lowed the method described by Torisawa.
II 3-nitrobenzylidene-1-(3-chloropropyl) indoline-2-one; the
synthesis followed the method described by Messaoudi.
III 3-nitrobenzylidene-1-(3-azidopropyl) indoline-2-one; the
synthesis followed the method described by Ortiz.
IV 3-nitrobenzylidene-1-(3-aminopropyl) indoline-2-one; the
synthesis followed the method described by De Almeida.
To a stirred solution of 2.5 ml bicarbonate buffer (0.02 M,
pH 9.3), PH II-7 amino-propyl-side chain derivative (4 mg) and
FITC (4 mg) were added; the mixture was incubated at room
temperature for 17 hours and then purified by thin-layer
chromatography (acetidin:ligroin, 10:1, vol/vol). The mixture
was evaporated under reduced pressure to yield the FITC labeled
PH II-7 derivative as a maroon solid: Rf 0.1, yield 86%, mp 188–
189uC, 1H NMR [CDCl3, 400 MHz]: d=0.91 (t, J=7.2Hz,
3H, CH3), 1.36–1.43 (m, 2H, CH2), 1.63–1.68 (m, 2H, CH2),
3.34 (d, J=6.0 Hz, 2H, CH2), 7.13 (t, J=8 Hz, 1H), 7.36 (d,
J=7.6Hz,1H),7.58(d,J=7.6 Hz, 1H), 10.52 (s, 1H, NH). ESI-
MS: (M-) m/z (%)=282 (100); Anal. Calc’d for C12H14ClN3OS.
(283.78): C, 50.79; H, 4.97; N, 14.81. Found: C, 50.52; H, 4.71;
N, 14.80.
Compound IV and FITC (1:1) mixture were incubated at room
temperature for 17 hours and then bonded products were purified
by thin-layer chromatography.
Confocal Microscopy
Images of the numbered and subcultured cells in 6-well plates
were obtained using a confocal fluorescence microscope (Leica,
Nussloch, Germany). Adriamycin can be activated by 500–
566 nm wavelength green excitation laser, and emits 620 nm
wavelength red fluorescence [70–72], we used 544 nm wavelength
excitation laser in this experiment. 488 nm/522 nm were set as
the excitation and emission wavelengths of FITC labeled PH II-7
respectively.
Genome profile analysis
The K562 and K562/A02 cells were treated with PBS or PH II-
7 (200 nM) for 48 hours, and the total RNA was extracted,
reversed transcribed to cDNA, then in vitro transcribed to cRNA,
and hybridized to the HGU 133 plus 2 arrays, which were then
scanned and analyzed using Affymetrix GeneChip Operating
Software (GCOS) version 1.4. The GCOS algorithm analyzes
data in the following ways (1) determine whether calls of individual
genes are present or not by evaluating probe pairs for matching
status; (2) normalize raw gene expression values and calculate their
relative expression levels; and (3) statistically decide the relative
gene expression variation. Transcripts with expression intensities
lower than 100 in all samples were excluded since the extremely
low signal level could be intertwined with the background noise,
and the fold-changes tend to be distorted. Transcripts with an
absent call in all samples were also excluded. Significantly
expressed genes were defined as those with expression levels up-
regulated or down-regulated by more than a factor of 2.
Annotation analysis was conducted by R. Bioconductor, MeV.
Gene ontology analysis
Gene ontology (GO) analysis was performed with the online tool
of The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 [73,74], url: http://david.abcc.ncifcrf.
gov/.
Real-time PCR
Real-time polymerase chain reaction (PCR) was used with
GAPDH as the reference gene. The PCR reactions were done in a
final volume of 20 mL containing cDNA synthesized from 2 mg
total RNA (see above), 330 nM primers, and 10 mL SYBR-green
PCR master mix (Applied Biosystems, Foster City, CA). Results
from at least 4 separate experiments were calculated using the
7500 system Sequence Detection Software version 1.2.3 (Applied
Biosystems).
siRNA transfection
PKC-specific siRNA (Invitrogen) was transfected into leukemia
cells using Lipofectamine 2000 according to the protocol
recommended by the manufacturer. The effects of siRNA on
PKCA and MDR1 mRNA expression were examined 72 hours
after transfection by RT-PCR.
Western blot analysis for PKCA
K562/A02 cells (5610
5/ml) were treated with PH II-7, TPA,
Calphostin C or PKC-specific siRNA at 37uC for 72 hours.
Harvested cell pellets were suspended in PBS and then lysed in
lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP40,
0.5% sodium deoxycholate, 1 mM DTT, 0.1% SDS, 1 mM
ethylene diamine tetraacetic acid, 100 mg/L PMSF, and 1 mg/L
aprotinin). Equal amounts of cell lysate were separated on 12%
Tris-glycine-SDS polyacrylamide gels and proteins were electro-
blotted onto nitrocellulose membranes. Proteins were identified
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was performed using horseradish peroxidase-conjugated second-
ary antibody and Super Signal West Pico Chemiluminescent
Substrate (Pierce Inc, Rockford, IL) according to the manufac-
turers’ instructions.
Flow cytometry analysis for P-gp
P-gp expression was analyzed by flow cytometry. Briefly, K562/
A02 cells (5610
5/ml) were exposed to PH II-7, TPA, Calphostin
C or PKCA-targeted siRNA at 37uC for 72 hours. Harvested cell
pellets were resuspended in PBS. About 1610
6 cells were
incubated with phycoerythrin–conjugated P-gp or polyclonal
human IgG as a nonbinding control in a final volume of
0.2 mL. Incubation was continued for an additional 60 minutes
on ice. After 2 washes with serum-free medium, cells were
analyzed using flow cytometry.
Supporting Information
Table S1 IC50 values of the derivatives of PH II-7 in various
human tumor cell lines.
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